MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts

PURPOSE: Investigate the efficacy and pharmacodynamic effects of MK-1775, a potent Wee1 inhibitor, in both monotherapy and in combination with gemcitabine using a panel of p53-deficient and p53-wild type human pancreatic cancer xenografts. EXPERIMENTAL DESIGN: Nine individual patient-derived pancrea...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Rajeshkumar, N.V., De Oliveira, Elizabeth, Ottenhof, Niki, Watters, James, Brooks, David, Demuth, Tim, Shumway, Stuart D., Mizuarai, Shinji, Hirai, Hiroshi, Maitra, Anirban, Hidalgo, Manuel
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3307341/
https://ncbi.nlm.nih.gov/pubmed/21389100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2580
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados